AMED’s initiative to advance DDS evaluation research

Tetsuya Kusakabe

Japan Agency for Medical Research and Development, Department of Innovative Drug Discovery and Development

Development of in vivo production technology of engineered exosomes by nanoDDS

Rikinari Hanayama

WPI Nano Life Science Institute, Kanazawa University

Takashi Nakamura

Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University

Frontiers in Cancer Drug Discovery: Integrating Nucleic Acid Therapeutic Seeds with Drug Delivery Systems

Akihide Yoshimi

Division of Cancer RNA Research, National Cancer Center Research Institute

Nobuhiro Nishiyama

Institute of Integrated Research, Institute of Science Tokyo / Innovation Center of Nanomedicine (iCONM), Kawasaki Institute of Industrial Promotion

Challenges in the development of nucleic acid medicines for neurodegenerative diseases by integrating nose-to-brain DDS and HDO technologies

Takanori Kanazawa

Graduate School of Biomedical Sciences, Tokushima University
Innovative Research Center for Drug Delivery System, Tokushima University

Hidefumi Mukai

Graduate School of Biomedical Sciences, Nagasaki University

DDS Consortium initiatives and collaboration with academia stemming from JPMA activities

Takashi Nozawa

Astellas Pharma Inc.

Translating DDS-Based Nucleic Acid Therapeutics: Exit Strategies from Bench to Market

Robert Langer

Massachusetts Institute of Technology

Issues for pharmaceutical business of RNA and nucleic acid medicines

Shiro Akinaga

NANO MRNA Co., Ltd.

The Patent Application Trends Survey in FY2024 “mRNA medicines”

Riko Toyahara

Patent Examination Department (Chemistry, Life Science and Material Science), Japan Patent Office

Noriko Shinohara

Examination Research Office, Patent Examination Department (Chemistry, Life Science and Material Science), Japan Patent Office

Trends in the Nucleic Acid Drug Market from the Perspective of Analyst

Tsuzuki Shinya

Nxera Pharma

Current Landscape and Future Challenges of Business Development for siRNA-based Nucleic Acid Drugs

Kumiko Ui-Tei

NucleoTIDE and PepTIDE Drug Discovery Center, Institute of Integrated Research, Institute of Science Tokyo

Overview of National Cancer Center Venture Incubation Program (NCC VIP) and the Next Startup Support Program in NCC

Akihiro Sato

Center for Promotion of Translational Research / Hospital East, National Cancer Center

Pattern Recognition of Chemical Structures and ADMET Prediction by Language AI

Tadahaya Mizuno

Graduate School of Pharmaceutical Sciences, The University of Tokyo

Laboratory automation for efficient drug discovery research

Naruki Yoshikawa

Division of Computational Drug Discovery and Design, Medical Research Laboratory, Institute of Integrated Research, Institute of Science Tokyo

Data-Driven Approaches in Drug Discovery and Vaccine Development

Yayoi Natsume-Kitatani

Artificial Intelligence Center for Health and Biomedical Research, National Institutes of Biomedical Innovation, Health and Nutrition

Computational mass spectrometry to deepen the understanding of metabolite diversity

Hiroshi Tsugawa

Tokyo University of Agriculture and Technology, Department of Biotechnology and Life Science

AI-driven multimodality drug discovery

Masahito Ohue

School of Computing, Institute of Science Tokyo

Therapeutic In Vivo Synthetic Chemistry

Katsunori Tanaka

Department of Chemical Science and Engineering, Institute of Science Tokyo
Biofunctional Synthetic Chemistry laboratory, RIKEN Pioneering Research Institute

JigSAP -Sustained-Release Peptide Hydrogel - for the Treatment of Ischemic Stroke

Itsuki Ajioka

Center for Brain Integration Research (CBIR), Institute of Integrated Research (IIR), Institute of Science Tokyo

Nanomedicines for immunotherapy

Horacio Cabral

Department of Bioengineering, Graduate School of Engineering, The University of Tokyo

Regulation of cellular phenotypes with disk-shaped polymer micro-patches and its application to solid tumor treatment including glioblastoma

Tatsuya Fukuta

Department of Physical Pharmaceutics, School of Pharmaceutical Sciences, Wakayama Medical University

Biomolecule Delivery Systems Based on Combination of Polyphenol and Precision Synthetic Polymers for Potential Application to Gene Therapy

Yuto Honda

Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology

Deepening and Advancing ADC Technology

Shino Manabe

Laboratory of Synthetic Biomolecular Chemistry, School of Pharmacy and Pharmaceutical Sciences, Hoshi University

Applications to Various Antibody Conjugates Using Antibody Site-Specific Conjugation Method AJICAP®

Tomohiro Fujii

Ajinomoto Co., INC

Research and development of antibody-drug conjugates (ADCs) loaded with a potent DNA topoisomerase I inhibitor

Takashi Nakada

Modality Research Laboratories I Research Function R&D Division, Daiichi Sankyo Co., Ltd.

Broad-spectrum efficacy of CEACAM6-targeted antibody–drug conjugate with BET protein degrader in solid tumor mouse models

Hiroyuki Kogai

Cell Lineage & Differentiation Domain, DHBL, Eisai Co. Ltd.

Advance of Cyclic Peptides in Radiopharmaceuticals and Beyond Using PeptiDream's Peptide Drug Platform System (PDPS) Technology

Masato Murakami

Chief Medical Officer of PeptiDream Inc.
President and Representative Director of PDRadiopharma Inc.
Vice President, Japan Radiopharmaceuticals Association (JRPA)

Trends of the cosmetics industry's efforts for alternatives to animal experiments

Akiko Tamura

Brand Value R&D Institute, Shiseido Co., Ltd.

Animals and Alternatives to animal experiments - Expectations for the correlation including MPS

Yuzuru Ito

Faculty of Life and Environmental Sciences, University of Tsukuba

Advancement of MPS Research for Animal Alternatives in Pharmaceutical Industry

Wataru Obuchi

Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd.

Shaping the Future of Experimental Animals with Mice

Aya Uchida

The Jackson Laboratory Japan, Technical Information Services

Standardization of alternatives to animal testing and the role of JaCVAM

Takao Ashikaga

National Institute of Health Sciences, Division of Genome Safety Science

Development of next-generation vaccines and DDS - What is the role of DDS researchers in the development of next-generation vaccines ? -

Fuminori Sakurai

Faculty of Pharmacy, Kindai University

Next-generation vaccine against novel coronaviruses

Daisuke Muraoka

Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute

Next-generation vaccine development based on DDS for nucleic acid adjuvants and antigens

Makiya Nishikawa

Faculty of Pharmaceutical Sciences, Tokyo University of Science

Utilization of Bacterium-like Particles for Vaccine Antigen Delivery

Keita Takahashi

Gifu Pharmaceutical University, Laboratory of Microbiology and Immunology

Research and Development of mRNA Vaccine “Daichirona”

Toshihiro Kiho

Daiichi-Sankyo R&D Division Vaccine Research Laboratories

Development of Anti-senescence Therapy Targeting Seno-Anergy

Tohru Minamino

Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine

Development trends and future prospects for nucleic acid-based modalities

Takao Inoue

National Institute of Health Sciences

Anticancer effects of nucleic acid aggregates

Akimitsu Okamoto

Department of Chemistry and Biotechnology, Graduate School of Engineering, The University of Tokyo

Nucleic acid adjuvant system-based cancer immunotherapy

Takashi Nakamura

Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University

Development of anti-cancer siRNA therapeutics targeting the transcription factor PRDM14, a molecule responsible for cancer stem cell properties.

Hiroaki Taniguchi

Division of Innovative Cancer Control Research, Cancer Research Institute of Kanazawa University

Development of mRNA vaccines and therapeutics against infectious diseases and our efforts toward future clinical translation

Satoshi Uchida

Department of Advanced Nanomedical Engineering, Medical Research Laboratory, Institute of Integrated Research, Institute of Science Tokyo

Drug Delivery System in radioimmunotherapy with astatine-211

Hiroki Takashima

Division of Developmental Therapeutics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center

Development of Radioisotope Labeling Techniques and Their Application to Radiotheranostic　Probes

Hiroyuki Kimura

Agency for Health, Safety and Environment, Kyoto University

Development of radiotheranostic antibody drug for pancreatic cancer and its basic research

Naoaki Yamada

Research Center, Nihon Medi-Physics Co. Ltd.

Preclinical evaluation of Cadherin 3 (CDH3) -targeted alpha particle emitting radiopharmaceutical therapy, 225Ac-PPMX-T002 for the treatment of solid cancer

Shinji Hagiwara

Research and Development Division, Perseus Proteomics Inc.

Targeted alpha therapy using astatine: from preclinical to clinical applications

Tadashi Watabe

Graduate School of Medicine, The University of Osaka

Development of a near-infrared (NIR) dye for photoimmunotherapy and its application

Kenjiro Hanaoka

Graduate School of Pharmaceutical Sciences, Keio University

Exosome Hijacking DDS and Light-Triggered Genome Editing

Asako Yamayoshi

Department of Life Science and Technology, Institute of Science Tokyo

Polymer design for enhanced drug delivery

Kanjiro Miyata

Graduate School of Engineering, The University of Tokyo

Molecular targeted chemogenetics: cell-type-specific control of cell-surface receptors in vivo

Shigeki Kiyonaka

Graduate School of Engineering, Nagoya University

Development and Application of DDS Carrier Peptides

Yosuke Demizu

Division of Organic Chemistry, National Institute of Health Sciences

Prodrugation of bispecific antibodies leading to cancer-specific functionalization

Ryutaro Asano

Dept. of Biotech. & Life Sci., Grad. Sch. of Eng., Tokyo Univ. of Agric. & Tech.

Granting BBB-penetrating ability to antibody drugs using LassoGraft technology

Junichi Takagi

Institute for Protein Research, The University of Osaka

Development of antibody-drug conjugates using AccumBody, tissue-specific delivering antibody

Yuji Ito

Department of Science, Graduate School of Science and Engineering, Kagoshima University

Catalytic antibody (Antigenase) directly damaging cancer cell

Emi Hifumi

Institute for Research Management, Oita University

Novel antibody engineering technologies enabling subcutaneous anti-complement C5 antibody therapy

Kenta Haraya

Research Division, Discovery Biologics Department, Chugai Pharmaceutical Co., Ltd.

Clinical development of Crovalimab dosage optimization - beyond the drug-target-drug complex -

Tomohisa Saito

Chugai Pharmaceutical. Co., Ltd. Pharmaceutical Science department